Terms: = Ovarian cancer AND PR, PGR, progesterone receptor AND Treatment
622 results:
1. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
2. High incidence of imperforate vagina in ADGRA3-deficient mice.
Kvam JM; Nybo ML; Torz L; Sustarsic RK; Jensen KHR; Nielsen JE; Frederiksen H; Gadgaard S; Spiess K; Poulsen SS; Thomsen JS; Cowin P; Blomberg Jensen M; Kurita T; Rosenkilde MM
BMC Biol; 2024 Apr; 22(1):77. PubMed ID: 38589878
[TBL] [Abstract] [Full Text] [Related]
3. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
Yuan H; Li N; Wu L; Yao H
J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
[TBL] [Abstract] [Full Text] [Related]
4. Mesonephric-like adenocarcinoma of the ovary.
Yang Y; Zhao M; Jia Q; Tang H; Xing T; Li Y; Tang B; Xu L; Wei W; Zheng H; Shi R; Xia B; Chen J
J Ovarian Res; 2024 Mar; 17(1):57. PubMed ID: 38444000
[TBL] [Abstract] [Full Text] [Related]
5. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
[TBL] [Abstract] [Full Text] [Related]
6. The management of uterine tumor resembling an ovarian sex cord tumor (UTROSCT): case series and literature review.
Lin J; Liu L; Wang L; Ma N; Zhang K; Xie N; Yu H; Deng S; Sun Y
World J Surg Oncol; 2024 Feb; 22(1):42. PubMed ID: 38310233
[TBL] [Abstract] [Full Text] [Related]
7. A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
Cristea MC; Stewart D; Synold T; Ruel N; Mortimer J; Wang E; Jung A; Wilczynski S; Konecny GE; Eng M; Kilpatrick L; Han E; Dellinger T; Hakim A; Lee S; Morgan RJ; Wakabayashi MT; Frankel PH
Gynecol Oncol; 2024 Mar; 182():124-131. PubMed ID: 38262235
[TBL] [Abstract] [Full Text] [Related]
8. Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer.
Qin Y; Huang S; Tang J; Fan Y; Deng X; Guan P; Zhang Z; Wen Q; Li D
Front Immunol; 2023; 14():1329951. PubMed ID: 38235148
[TBL] [Abstract] [Full Text] [Related]
9. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.
Ju J; Gao SL; Wang JY; Sang D; Kang YK; Wang X; Yue J; Shuai Y; Qi YX; Yuan P
Thorac Cancer; 2024 Feb; 15(6):439-447. PubMed ID: 38185807
[TBL] [Abstract] [Full Text] [Related]
11. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
12. P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Bates M; Mullen D; Lee E; Costigan D; Heron EA; Kernan N; Barry-O'Crowley J; Martin C; Keegan H; Malone V; Brooks RD; Brooks DA; Logan JM; Martini C; Selemidis S; McFadden J; O'Riain C; Spillane CD; Gallagher MF; McCann A; O'Toole S; O'Leary JJ
Pathol Res Pract; 2024 Jan; 253():155020. PubMed ID: 38103365
[TBL] [Abstract] [Full Text] [Related]
13. A review of phase II and III drugs for the treatment and management of endometriosis.
Perrone U; Evangelisti G; Laganà AS; Bogliolo S; Ceccaroni M; Izzotti A; Gustavino C; Ferrero S; Barra F
Expert Opin Emerg Drugs; 2023 Dec; 28(4):333-351. PubMed ID: 38099328
[TBL] [Abstract] [Full Text] [Related]
14. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With
Meric-Bernstam F; Rothe M; Mangat PK; Garrett-Mayer E; Gutierrez R; Ahn ER; Cannon TL; Powell S; Krauss JC; Reynolds CM; von Mehren M; Behl D; Calfa CJ; Duvivier HL; Kaplan HG; Livingston MB; Sharma MR; Urba WJ; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300385. PubMed ID: 38096472
[TBL] [Abstract] [Full Text] [Related]
15. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab treatment in Patients with Advanced ovarian cancer.
Kos FJ; Frankel P; Cristea M; Eng M; Tinsley R; Dempsey S; Ruel N; Stewart D; Dellinger TH; Diamond DJ
Cancer Res Commun; 2023 Dec; 3(12):2585-2595. PubMed ID: 38032111
[TBL] [Abstract] [Full Text] [Related]
16. The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death.
Koyanagi T; Saga Y; Takahashi Y; Tamura K; Yoshiba T; Takahashi S; Taneichi A; Takei Y; Mizukami H; Fujiwara H
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1934. PubMed ID: 38013666
[TBL] [Abstract] [Full Text] [Related]
17. Steroid profile in patients with breast cancer and in mice treated with mifepristone.
Elía A; Saldain L; Lovisi S; Martínez Vazquez P; Burruchaga J; Lamb CA; Lüthy IA; Diez F; Homer NZM; Andrew R; Rojas P; Lanari C
Endocr Relat Cancer; 2024 Feb; 31(2):. PubMed ID: 37962553
[TBL] [Abstract] [Full Text] [Related]
18. [Risk factor analysis of lymph node metastasis in endometrial carcinoma combined with molecular types].
Li LL; Li H; Li J; Zhang XB; Wang ZQ; Shen DH; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):733-741. PubMed ID: 37849254
[No Abstract] [Full Text] [Related]
19. Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies.
Kim M; Chang CS; Choi MC; Lee JW; Park H; Joo WD
Yonsei Med J; 2023 Oct; 64(10):587-592. PubMed ID: 37727917
[TBL] [Abstract] [Full Text] [Related]
20. Blood Plasma Small Non-Coding RNAs as Diagnostic Molecules for the progesterone-receptor-Negative Phenotype of Serous ovarian Tumors.
Timofeeva AV; Fedorov IS; Asaturova AV; Sannikova MV; Tregubova AV; Mayboroda OA; Khabas GN; Frankevich VE; Sukhikh GT
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569592
[TBL] [Abstract] [Full Text] [Related]
[Next]
